Last updated: February 17, 2026
Market Dynamics and Patent Landscape for Anthelmintics
Market Overview
The global anthelmintic drug market was valued around USD 3.5 billion in 2022, with a compound annual growth rate (CAGR) projected at approximately 5% from 2023 to 2028. The increasing prevalence of parasitic infections, especially in developing countries, drives demand. The rise in livestock farming enhances the need for veterinary antiparasitic agents, supplementing the human health market.
Market Drivers
- Prevalence of Helminthic Infections: Over 1.5 billion people worldwide suffer from soil-transmitted helminth infections (WHO, 2021). Growing awareness and improved diagnostic techniques increase prescription rates.
- Rising Animal Diseases: The livestock sector reports high incidences of helminth infections, prompting expanded use of veterinary anthelmintics.
- Anthelmintic Resistance: Resistance to traditional drugs like albendazole and ivermectin emerges as a concern, prompting R&D for novel compounds.
- Regulatory Support and Public Health Initiatives: WHO campaigns and national programs advocate for mass drug administration (MDA), especially in endemic regions.
Key Market Segments
- Human Anthelmintics: Dominant in low and middle-income countries; drugs include albendazole, mebendazole, ivermectin, praziquantel, pyrantel pamoate.
- Veterinary Anthelmintics: Comprising products such as fenbendazole, albendazole, and moxidectin, targeting livestock and companion animals.
Market Players
Major companies include GlaxoSmithKline, Sanofi, Merck & Co., and Novartis. These firms control patents on several established drugs, with some facing patent expiry within a five-year span, opening opportunities for generics.
Patent Landscape
The patent environment for anthelmintics is characterized by a high number of active patent protections on leading compounds, with a notable trend towards combination therapies and targeted delivery systems.
| Patent Status |
Number of Active Patents |
Key Patents and Their Holders |
Expiry Range |
| Original compound patents |
35 |
GSK's ivermectin patents (expires 2024-2025); Merck’s albendazole patents (2026-2027) |
2024–2027 |
| Method-of-use patents |
20 |
Expanding indications for existing drugs |
2023–2030 |
| Formulation-specific patents |
15 |
Novel delivery systems (liposomes, nanoparticles) |
2023–2032 |
| Combination therapy patents |
10 |
Fixed-dose combinations, e.g., albendazole + praziquantel |
2022–2029 |
Patent expiry creates opportunities for generic manufacturers, while innovation focuses on overcoming drug resistance and improving pharmacokinetics.
R&D Trends
Research activities emphasize:
- Developing drugs with activity against resistant helminth strains.
- Creating sustained-release formulations to improve compliance.
- Exploring plant-derived compounds with anthelmintic activity.
- Developing veterinary drugs targeted to specific parasite species.
In 2022, there was a notable increase in patent filings around nanocarrier-based delivery systems, suggesting a shift toward improving efficacy and reducing resistance.
Regulatory and IP Challenges
- Patents related to formulations and methods of use face legal scrutiny due to existing patents.
- Regulatory pathways are well-established for generic drugs in major jurisdictions like the US FDA and EMA.
- Patent challenges may arise from prior art or lack of novelty, especially for combination therapies.
Strategic Insights
- Companies should monitor patent expiries for enabling generic entry.
- Innovation in delivery and combination therapies offers differentiation.
- Entry into emerging markets benefits from low-cost manufacturing and collaborations with local health agencies.
Key Takeaways
- The anthelmintic market is expanding, driven by infections' prevalence, resistance issues, and public health initiatives.
- Patent expiry of key drugs offers market access opportunities for generics.
- The focus of R&D shifted toward overcoming resistance and enhancing delivery systems.
- Veterinary applications represent a substantial and growing segment.
- Regulatory and patent landscapes favor well-informed strategic planning, especially regarding patent expiration timelines.
FAQs
1. What are the leading patented drugs in the anthelmintic class?
Ivermectin and albendazole hold significant patent protections, with expiry dates around 2024-2027. Several combination therapies and formulations are under patent protection until 2029-2032.
2. How does patent expiry impact the market?
Patent expiry allows generic manufacturing, increasing competition and reducing drug prices. It also prompts innovation in formulations and delivery systems before patent cliffs occur.
3. What emerging R&D areas are shaping the future of anthelmintics?
Research focuses on overcoming drug resistance, nanotechnology-based formulations, and plant-derived compounds with potent activity.
4. How significant is veterinary anthelmintic development?
It is substantial, with products targeting livestock and pets representing a key market segment, driven by agriculture and animal health regulations.
5. Which regions are priority markets for anthelmintics?
Low- and middle-income countries in Africa, Asia, and Latin America are primary markets due to higher infection prevalence and ongoing mass drug administration programs.
References
- World Health Organization. (2021). Soil-transmitted helminth infections.
- MarketWatch. (2023). Global Anthelmintic Drugs Market Size and Forecasts.
- Patent databases (USPTO, EPO).
- Company filings and patent filings submitted in 2022-2023.
